What’s Next? Five Things To Look Out For In March

Bristol Myers Squibb Braces For US Impact To Revlimid And Abraxane

This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.

What's Next Image
Revlimid Gx Launch Dominates That March News • Source: Informa

More from Biosimilars

More from Products